Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Express Scripts
Federal Trade Commission
McKinsey
Daiichi Sankyo
Moodys
UBS
Accenture
Cipla

Generated: April 26, 2018

DrugPatentWatch Database Preview

EPROSARTAN MESYLATE Drug Profile

« Back to Dashboard

Which patents cover Eprosartan Mesylate, and when can generic versions of Eprosartan Mesylate launch?

Eprosartan Mesylate is a drug marketed by Mylan Pharms Inc and is included in one NDA.

The generic ingredient in EPROSARTAN MESYLATE is eprosartan mesylate. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the eprosartan mesylate profile page.
Drug patent expirations by year for EPROSARTAN MESYLATE
Pharmacology for EPROSARTAN MESYLATE
Synonyms for EPROSARTAN MESYLATE
(|AE)-|A-[[2-Butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-2-thiophenepropanoic Acid Monomethanesulfonate
(E)-|A-[[2-Butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-2-thiophenepropanoic Acid Methanesulfonate
(E)-2-Butyl-1-(p-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid, monomethanesulfonate
(E)-2-butyl-1-(p-carboxybenzyl)-alpha-2-thienylimidazole-5-acrylic acid monomethanesulfonate
(E)-4-((2-butyl-5-(2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl)-1H-imidazol-1-yl)methyl)benzoic acid compound with methanesulfonic acid (1:1)
(E)-alpha-((2-butyl-1-((4-carboxyphenyl)methyl)-1H-imidazol-5-yl)methylene)-2-thiophenepropanoic acid monomethanesulfonate
143E964
144143-96-4
2-Thiophenepropanoic acid, alpha-((2-butyl-1-((4-carboxyphenyl)methyl)-1H-imidazol-5-yl)methylene)-, (E)-, monomethanesulfonate
4-({2-butyl-5-[(1E)-2-carboxy-3-(2-thienyl)prop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid methanesulfonate
4-[[2-Butyl-5-(2-carboxy-3-thiophen-2-yl-prop-1-enyl)-imidazol-1-yl]methyl]benzoic acid mesylate
4-[[2-butyl-5-[(E)-2-carboxy-3-thiophen-2-ylprop-1-enyl]-1-imidazolyl]methyl]benzoic acid; methanesulfonic acid
4-[[2-butyl-5-[(E)-2-carboxy-3-thiophen-2-ylprop-1-enyl]imidazol-1-yl]methyl]benzoic acid;methanesulfonic acid
4-[[2-butyl-5-[(E)-3-hydroxy-3-oxo-2-(thiophen-2-ylmethyl)prop-1-enyl]imidazol-1-yl]methyl]benzoic acid; methanesulfonic acid
4-[[2-butyl-5-[(E)-3-oxidanyl-3-oxidanylidene-2-(thiophen-2-ylmethyl)prop-1-enyl]imidazol-1-yl]methyl]benzoic acid; methanesulfonic acid
8N2L1NX8S3
92605-EP2295430A2
92605-EP2295431A2
92605-EP2305670A1
A808180
AB0069224
AC1NR04M
AK110450
AKOS015994738
AM84399
AOB5517
C23H24N2O4S.CH4O3S
CAS-144143-96-4
CCG-222112
CHEBI:48409
CHEMBL1200987
CS-2291
D02082
DJSLTDBPKHORNY-XMMWENQYSA-N
DSSTox_CID_24217
DSSTox_GSID_44217
DSSTox_RID_80124
DTXSID7044217
E1161
Epro-sartan mesylate dihydrate
Eprosartan (mesylate)
Eprosartan mesilate
Eprosartan mesylate (USAN)
Eprosartan mesylate [USAN:BAN]
Eprosartan mesylate dihydrate
Eprosartan mesylate, >=98% (HPLC)
Eprosartan mesylate, United States Pharmacopeia (USP) Reference Standard
Eprosartan mesylate|SK&F 108566|(?E)-?-[[2-Butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-2-thiophenepropanoic acid methanesulfonate
eprosartan methanesulfonate
Eprosartan Monomethanesulfonate
Futuran
HE070981
HMS3262B17
HY-15834A
J-007923
KS-1233
LS-173203
MFCD08141807
MP-0196
Navixen
NCGC00164557-01
NCGC00167505-02
NCGC00261493-01
Regulaten
s4102
SCHEMBL41396
SK&F 108566-J
SK&F-108566-J
SK&F-108566J
SKF 108566
SKF-108566J
SR-05000001450
SR-05000001450-2
ST2412854
sunitinib and its intermediate
Teveten
Teveten (TN)
Teveten SB
Tevetenz
Tox21_112186
Tox21_112186_1
Tox21_500808
UNII-8N2L1NX8S3

US Patents and Regulatory Information for EPROSARTAN MESYLATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Pharms Inc EPROSARTAN MESYLATE eprosartan mesylate TABLET;ORAL 202012-001 Nov 16, 2011 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Mylan Pharms Inc EPROSARTAN MESYLATE eprosartan mesylate TABLET;ORAL 202012-002 Nov 16, 2011 AB RX No Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Medtronic
US Department of Justice
Express Scripts
McKinsey
Farmers Insurance
Cipla
McKesson
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.